746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint
Linong Ji,Andrew Ahmann,Bo Ahren,Matthew Capehorn,Ping Hu,Ildiko Lingvay,Wenyan Liu,Helena W. Rodbard,Zewei Shen,Christopher H. Sorli
DOI: https://doi.org/10.2337/db23-746-p
IF: 7.7
2023-01-01
Diabetes
Abstract:Hyperglycemia, high BP and dyslipidemia are common risk factors for CVD. The aim of this study was to assess the proportion of participants treated with once-weekly (OW) semaglutide, or a comparator, achieving a metabolic composite target endpoint in the SUSTAIN trials. Participants from SUSTAIN 1-5, 7-10 and SUSTAIN China with uncontrolled T2D treated with OW semaglutide vs comparators (incl. placebo) were pooled, and the proportion achieving the endpoint (HbA1c <7%, BP <140/90 mmHg and non-HDL cholesterol <130 mg/dL) was assessed. Endpoints were analyzed using on treatment without rescue medication data for each trial, using a binomial logistic regression model with treatment, region/country, and stratification factor as fixed effects and baseline value (HbA1c/BP/Non-HDL) as covariate. Pooled analysis was conducted using logistic regression with treatment and trial as fixed effects and baseline value as covariate. Treatment with 0.5 and 1 mg OW semaglutide was associated with higher odds (OR range 1.4-24.4) of achieving the endpoint vs comparators (Figure). The proportion of participants reaching the composite endpoint across all trials was 24% and 32% for 0.5 mg and 1.0 mg semaglutide, respectively, vs 11% for comparators (p<0.0001). The results indicate that OW semaglutide may assist with the co-management of T2D and cardiometabolic risk factors, which could reduce the risk of CVD in people with T2D. Disclosure L.Ji: Other Relationship; Eli Lilly and Company, Novo Nordisk, Merck & Co., Inc., Bayer Inc., Sanofi-Aventis U.S., Roche Pharmaceuticals, MSD Life Science Foundation, AstraZeneca, Boehringer Ingelheim Inc., Abbott, Metronics. C.H.Sorli: Employee; Acerus Pharmaceuticals. A.Ahmann: Advisory Panel; Medtronic. B.Ahrén: Speaker's Bureau; Novo Nordisk, Nestlé Health Science, Stock/Shareholder; Novo Nordisk, AstraZeneca, Eli Lilly and Company. M.Capehorn: Advisory Panel; Novo Nordisk, Lilly Diabetes, Boehringer Ingelheim Pharmaceuticals Inc., Research Support; Boehringer Ingelheim Inc., Novo Nordisk, Lilly, Speaker's Bureau; Novo Nordisk, Lilly, Boehringer Ingelheim Inc. P.Hu: Employee; Novo Nordisk (China). I.Lingvay: Advisory Panel; Novo Nordisk A/S, Lilly Diabetes, Boehringer-Ingelheim, Sanofi, Consultant; Carmot Therapeutics, Inc., Merck Sharp & Dohme Corp., Janssen Scientific Affairs, LLC, Pfizer Inc., Intercept, Intarcia, Valeritas, TargetRWE, Shionogi, Zealand Pharma, Structure, Bayer, Research Support; Novo Nordisk A/S, Boehringer-Ingelheim. W.Liu: Employee; Novo Nordisk (China). H.W.Rodbard: Advisory Panel; Merck Sharp & Dohme Corp., Pacira BioSciences, Inc., Research Support; Eli Lilly and Company, Medtronic, Sanofi, Novo Nordisk. Z.Shen: Employee; Novo Nordisk (China).